Reviewer’s report

**Title:** Fingolimod in a patient with pulmonary arterial hypertension

**Version:** 1  **Date:** 11 May 2014

**Reviewer:** Ondrej Dolezal

**Reviewer’s report:**

**Major compulsory revisions:**

1) In the paper patient’s clinical symptoms and various scales/ scores are mentioned (eg NYHA). Pulmonary hypertension is not assumed to be absolute contraindication for FTY treatment and guidelines are working with more general term "heart failure" (class III or IV). So I believe that this term should appear in the article, clarifying if patient was assumed to have heart failure (clinically dyspnoe, stenocardia etc.) - possibly explaining NYHA II in more general terms?

2) Brief explanation of E/I quotient will be beneficial.

3) Was patient’s pulmonary hypertension considered to be mild/moderate/severe?

Authors should consider the fact that majority of readers will be professionals of neurological background.

**Minor essential revisions:**

Authors should pay attention to abbreviations as some abbreviations are explained in the text (majority), some in table’s legend (NYHA, NT-proBNP) and some not at all (EDSS, JCV). Minor spelling issues (fife vs. five etc.)

**Discretionary revisions**

Authors could consider changing title to "Fingolimod in a patient with heart failure on the background of pulmonary hypertension and coronary artery disease" as this maybe better reflects complexity of the case, however I would leave that in authors’ hands.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests